TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01803373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Five 20-mg water dispersable tablets equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Five 20-mg water dispersable tablets equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Five 20-mg water dispersable tablets equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Five 20-mg water dispersable tablets equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Five 20-mg water dispersable tablets equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: 5 grams (ie,20mg/g) equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: 5 grams (ie,20mg/g) equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: 5 grams (ie,20mg/g) equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: 5 grams (ie,20mg/g) equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: 5 grams (ie,20mg/g) equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: 5 grams (ie,20mg/g) equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
Study: NCT03018561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and Cognitive testing
Description: Maximal cardiopulmonary test Rest cognitive testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and Cognitive testing
Description: Maximal cardiopulmonary test Rest cognitive testing
Study: NCT03186560

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gekoTM
Description: The geko™ W devices are small disposable, internally powered, neuromuscular stimulators that are applied externally to the leg. The W device has a fixed 27mA current. The devices are self-adhesive and are applied to the outer/posterior aspect of the knee. This positioning enables integral electrodes to apply a stimulus to the lateral popliteal nerve (often additionally termed the common peroneal) which branches from the sciatic nerve. This nerve controls the contraction of several muscles in the lower leg.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gekoTM
Description: The geko™ W devices are small disposable, internally powered, neuromuscular stimulators that are applied externally to the leg. The W device has a fixed 27mA current. The devices are self-adhesive and are applied to the outer/posterior aspect of the knee. This positioning enables integral electrodes to apply a stimulus to the lateral popliteal nerve (often additionally termed the common peroneal) which branches from the sciatic nerve. This nerve controls the contraction of several muscles in the lower leg.
Study: NCT03800524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic Acid
Description: * Tauroursodeoxycholic acid (TUDCA) 250 mg capsules~* Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~* Mode of administration: orally~* Duration: 18 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Placebo 250 mg capsules~* Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~* Mode of administration: orally~* Duration: 18 months
Study: NCT03890172

Intervention type: OTHER
Intervention: 20-100 ml venous blood will be drawn the from patient into sterilized centrifuge tube ,following centrifuge to separate PRP and at the bed side and tricked onto the ulcer twice weekly
Description: topical application of platelets rich plasma after Centrifugation at diabetic foot ulcer to study group ,history taking . Ankle brachial index (ABI) measuring and laboratory testes including hemoglobin A1c ( HgA1)c,cbc and prothrombin time( pt) and prothrombin concentration ( pc)

Intervention type: OTHER
Intervention: standard treatment
Description: Subjects in the control group will receive Standard Wound Care treatment for chronic ulcers according to accepted medical practices.
Study: NCT03971370

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)
Description: Essen post-exposure immunization schedule at day 0,3,7,14,28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)
Description: Zagreb post-exposure immunization schedule at day 0,7,21.
Study: NCT00497159

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo TID x 90 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: Dimebon 20 mg TID x 90 days
Study: NCT00854568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEOP regimen
Description: cyclophosphamide 750mg/m2 IV day 1 epirubicin 70mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1\~5 twice per day Or combined with rituximab 375mg/m2 IV day 0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP regimen
Description: cyclophosphamide 750mg/m2 IV day 1 doxorubicin 50mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1\~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
Study: NCT02954861

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00446225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg/day Patients will receive treatment until disease progression or unacceptable toxicity.~For all practical effects a treatment cycle will be defined as three weeks of continuous treatment with erlotinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Gemcitabine 1000 mg/m2 days 1 and 8 and Carboplatin AUC = 5 day 1, every 21 days.~Docetaxel (75 mg/m2) /carboplatin (AUC=6); Gemcitabine (1000 mg/m2; day 1 and 8) / Carboplatin (AUC=5)~Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabin
Description: Cisplatin (75 mg/m2) / Gemcitabine (1250 mg/m2; day 1 and 8) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
Study: NCT00518336

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling at Visit 3, 5 and 7.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling
Description: Blood sampling at Visit 3, 5 and 7.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of cervical specimen
Description: Collection of cervical specimen at Visit2, 3, 4, 5, 6 and 7.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Collection of cervical specimen
Description: Collection of cervical specimen at Visit2, 3, 4, 5, 6 and 7.
Study: NCT03971370

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human diploid cell rabies vaccine (Chengdu Kanghua Biological Products Co., Ltd.)
Description: Essen post-exposure immunization schedule at day 0,3,7,14,28.
Study: NCT03508921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Periprocedural Antibiotics
Description: One the day of injection, after eligibility is determined and consent obtained, research staff will refer to the randomization list to determine to which arm the patient is randomized. Patients randomized to the Procedural Antibiotics Only arm will receive a single dose of trimethoprim/sulfamethoxazole (800/160mg) peri-procedurally at the time of the first injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Periprocedural Antibiotics
Description: One the day of injection, after eligibility is determined and consent obtained, research staff will refer to the randomization list to determine to which arm the patient is randomized. Patients randomized to the Procedural Antibiotics Only arm will receive a single dose of trimethoprim/sulfamethoxazole (800/160mg) peri-procedurally at the time of the first injection.
Study: NCT01422785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clindamycin phosphate 1.2%/tretinoin 0.025% gel alone
Description: Once daily application of the clindamycin phosphate 1.2%/tretinoin 0.025% gel in the evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
Description: wash face with the benzoyl peroxide foaming cloth then rinse. then apply clindamycin phosphate 1.2%/tretinoin 0.025% gel. both done in the evening.
Study: NCT00518336

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Three doses administered intramuscularly at 0, 1 and 6 months.
Study: NCT05802290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 MG in 24 ML Injection
Description: nivolumab monotherapy at 240mg flat dose as a 30-minute IV infusion on Day 1 of a treatment cycle every 2 weeks (14 days) until confirmed progression of disease, unacceptable toxicity, death or withdrawal of consent
Study: NCT00603876

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almonds
Description: 100-110 grams (about 3/4 cupful)of almonds consumed daily for 28 days
Study: NCT00506740

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic scalpel
Description: A surgical instrument that uses ultrasonic energy that allows both cutting and coagulating at the precise point of application.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: monopolar electrosurgery generator and tip
Study: NCT03489538

Intervention type: PROCEDURE
Intervention: laparoscopic long limb roux-en-Y gastric bypass
Description: standard laparoscopic roux-en-Y gastric bypass (biliopancreatic limb 40 to 60 cm, alimentary limb 150 cm)
Study: NCT04684849

Intervention type: OTHER
Intervention: APP Diary
Description: Subjects keep a multi- item electronic digital App survey of symptoms for 2 weeks

Intervention type: OTHER
Intervention: APP Diary
Description: Subjects keep a multi- item electronic digital App survey of symptoms for 2 weeks

Intervention type: OTHER
Intervention: Paper Diary
Description: Subjects keep a multi-item paper survey of symptoms for 2 weeks

Intervention type: OTHER
Intervention: Paper Diary
Description: Subjects keep a multi-item paper survey of symptoms for 2 weeks
Study: NCT00060567

Intervention type: DRUG
Group type: OTHER
Intervention: E7070 + irinotecan combination
Description: Escalating doses starting from 125 mg/m2 irinotecan plus 250 mg/m2 E7070 combination.

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan + E7070 combination
Description: Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan + E7070 combination
Description: Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.
Study: NCT01633775

Intervention type: PROCEDURE
Intervention: Implantation of Ahmed glaucoma tube shunt, and Trabeculectomy with MMC
Description: In the Ahmed implant group, the tube shunts used were the valved 184-mm2 surface area (Model FP7; New World Medical, Inc, Rancho Cucamonga, California, USA). In the Trabeculectomy group, a routine trabeculectomy surgery was performed.

Intervention type: PROCEDURE
Intervention: Implantation of Ahmed glaucoma tube shunt, and Trabeculectomy with MMC
Description: In the Ahmed implant group, the tube shunts used were the valved 184-mm2 surface area (Model FP7; New World Medical, Inc, Rancho Cucamonga, California, USA). In the Trabeculectomy group, a routine trabeculectomy surgery was performed.
Study: NCT01805674

Intervention type: DIETARY_SUPPLEMENT
Intervention: isoflavones combined with magnolia
Description: 1 tablet/day duration: 12 weeks
Study: NCT00517725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carvedilol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bisoprolol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Study: NCT01576887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone Methyl 20 mg
Description: Oral, once daily
Study: NCT02364427

Intervention type: DEVICE
Intervention: Arterial stiffness - Vicorder to measure pulse wave velocity
Description: Pulse wave velocity (PWV)measures the stiffness of the arteries. This provides a simple and quick noninvasive method of obtaining the PWV for an arterial segment.
Study: NCT00351793

Intervention type: DEVICE
Intervention: Knee Implant
Description: Total knee replacement with Genesis II posterior stabilized knee
Study: NCT01576887

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, once daily
Study: NCT01814891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange maize feeding
Description: This group was fed orange maize.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A supplement
Description: This group received a dose of vitamin A at the estimated average requirement each feeding day of the intervention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oil only
Description: This group received a small amount of plain oil without vitamin A.
Study: NCT02050672

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-inositol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: untreated
Study: NCT02699840

Intervention type: BIOLOGICAL
Intervention: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: No vaccine will be provided as part of this study

Intervention type: BIOLOGICAL
Intervention: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: No vaccine will be provided as part of this study

Intervention type: BIOLOGICAL
Intervention: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: No vaccine will be provided as part of this study
Study: NCT02742155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play2Sleep
Description: Behavioral: Video self-modelling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison
Description: Behavioral: Information only
Study: NCT00536094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT includes 45-minute psychotherapy sessions once a week for a period of approximately 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: TAU includes 45-minute psychosocial treatment sessions once a week for a period of approximately 12 weeks.
Study: NCT00005066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O6-benzylguanine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Study: NCT00086242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Telephone Counseling (PTC)
Description: Eligible patients are randomized to receive psychosocial telephone counseling (PTC) or usual care.The PTC intervention was specifically designed to help women cope with the stressful events and feelings of distress associated with cervical cancer. The PTC arm of the study received six counseling sessions, \~45 to 50 min in length, in their preferred language, consisting of five consecutive weekly sessions and a 1-month booster session, delivered by a psychologist. A review letter, generated by the counselor after each session, recapitulated the session's contents and reinforced adaptive coping strategies.
Study: NCT00767494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost/Brinzolamide fixed combination
Description: Eye Drops, suspension once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost/Brinzolamide fixed combination
Description: Eye Drops, suspension once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azopt
Description: Eye Drop Suspension, 1 drop BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travatan
Description: Eye Drop Solution, 1 drop BID
Study: NCT03429166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills Training in Affective and Interpersonal Regulation
Description: A non-trauma-focused treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Therapy
Description: A non-trauma-focused treatment
Study: NCT04063540

Intervention type: DRUG
Group type: OTHER
Intervention: Amiloride
Description: Treatment by Amiloride vs placebo in crossover

Intervention type: DRUG
Group type: OTHER
Intervention: Amiloride
Description: Treatment by Amiloride vs placebo in crossover

Intervention type: DRUG
Group type: OTHER
Intervention: Placebos
Description: Treatment by Amiloride vs placebo in crossover

Intervention type: DRUG
Group type: OTHER
Intervention: Placebos
Description: Treatment by Amiloride vs placebo in crossover
Study: NCT01700595

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new technical intervention
Description: Contractures and broad scars of the subjects are treated by this surgical intervention which is a reconstructive surgery that is performed by the transfer of preexpanded perforator flaps to the recipient sites of skin deficiency.
Study: NCT03003013

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic Bone Graft Material (BGM) in Combination With Autologous Platelet-rich Fibrin (PRF)
Study: NCT04093895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PerioSept(r)
Description: Scaling and root planing followed by 3% PerioSept(r) administration
Study: NCT01634789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bazedoxifene
Description: 20 mg oral tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bazedoxifene
Description: 20 mg oral tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bazedoxifene
Description: 20 mg oral tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bazedoxifene/conjugated estrogens
Description: 20 mg / 0.625 mg oral tablet, single dose
Study: NCT01855516

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Study: NCT03980418

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DaTSCAN SPECT/CT in VERITON-CT camera
Description: the intervention is based on two recordings in camera VERITON-CT ; the first, in focus striatum mode and the second in brain focus mode
Study: NCT00276939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-fat, low-Glycemic Index, vegan diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat, low-Glycemic Index, vegan diet
Study: NCT01951586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zoledronic acid
Description: Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Denosumab
Description: Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
Study: NCT02052440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Treatment arm: baclofen 10mg tid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill by mouth three times daily
Study: NCT02496325

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound guided transperineal pudendal nerve block
Description: Children under general anesthesia were positioned supine, flexed legs and balls of the feet joined. A 12 MegaHertz (MHz) (38 mm) ultrasound probe was positioned on a horizontal axis passing through the ischial tuberosity, previously palpated.The probe was then moved medially on the axis, until the rectum appeared. Pudendal artery was identified if possible, using colour Doppler. The needle (22 Ga, 50 mm) was then introduced at the middle of the superior edge of the probe, in an out-of-plane approach. Tip of the needle was identified by direct vision, through displacement of adjacent anatomical structures or with saline injection. Nerve stimulation was started after placement of the tip of needle in the ischiorectal fossa, before local anaesthetic injection. After a negative aspiration test, a mix of Ropivacaine 2 % and clonidine 0.2µg/kg was injected in the ischiorectal fossa under ultrasound guidance.
Study: NCT01951586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Chemotherapy
Description: Standard of care chemotherapy consisting of pemetrexed or gemcitabine in combination with cisplatin or carboplatin administered according to local practice.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Chemotherapy
Description: Standard of care chemotherapy consisting of pemetrexed or gemcitabine in combination with cisplatin or carboplatin administered according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Zoledronic Acid
Description: Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.